CG Oncology is an oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with urologic cancer. CG Oncology sees a world where urologic cancer patients may benefit from its innovative therapies to live and work with dignity and an enhanced quality of life. Its lead asset, cretostimogene grenadenorepvec is an intravesically delivered oncolytic immunotherapy agent for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.